Cancer Vaccine Coalition and American Association for Cancer Research convene first-of-its-kind global think tank as immune-activating treatments reach a tipping point.
NEW YORK,
Jan. 27, 2026 /PRNewswire/ — Cancer vaccine research is entering a new phase as leading scientists join forces to coordinate the next stage of progress in cancer immunity.
Scientific advances in immunotherapy, technology, and immune system targeting have moved therapeutic cancer vaccines from theoretical promise toward clinical reality. The field is now entering a coordination phase aimed at accelerating patient access.
Against this backdrop, more than 50 of the world’s leading cancer vaccine researchers, clinicians, and cross-sector experts are meeting for
Transforming Cancer Care: A Global Think Tank to Accelerate Advances in Cancer Immunity, a first-of-its-kind effort designed to align priorities and advance progress across the field. The two-day think tank is organized by the Cancer Vaccine Coalition (CVC) in partnership with the American Association for Cancer Research (AACR) and hosted by HSBC Innovation Banking.
“This is a moment where coordination becomes the catalyst,” said Kristen Dahlgren, founder and CEO of the Cancer Vaccine Coalition, a breast cancer survivor, and former NBC
TODAY Show and
Nightly News correspondent. “I’ve seen the promising data from clinical trials. Patients need better therapies to help them beat cancer, and by working together, we can move advances through the system faster. With almost 1 in 2 of us expected to be diagnosed with cancer in our lifetime, there’s no time to waste.”
The think tank brings together leaders from top academic cancer centers, biotechnology and pharmaceutical companies, as well as policy and regulatory experts to establish shared priorities and actionable strategies to accelerate cancer vaccine development and delivery.
“Current immunotherapies successfully treat 20% of the deadliest cancers by unleashing the power of cancer-killing T cells,” said Elizabeth Jaffee, MD, deputy director of the Johns Hopkins Kimmel Cancer Center and co-chair of the two-day think tank. “Vaccines have the potential to increase the success of these immunotherapies in the other 80% of deadly cancers by creating cancer-killing T cells. The last decade of scientific discoveries has propelled vaccines toward becoming the next generation of successful immunotherapies for cancer treatment and prevention.”
Throughout the think tank, participants are focused on identifying practical solutions to shared challenges, including:
- Defining scientific priorities across cancer vaccine discovery, development, and implementation
- Improving efficiency across research and clinical translation pipelines
- Integrating emerging technologies such as AI-driven antigen prediction and novel delivery platforms
- Aligning funding strategies, regulatory pathways, and policy frameworks
- Establishing models for sustained global collaboration and equitable access
“AACR is honored to work with the Cancer Vaccine Coalition and the think tank sponsors to convene the top experts in the field this week,” said Margaret Foti, PhD, MD (hc), chief executive officer of AACR. “By bringing together an international group of dedicated, renowned researchers and patient advocates who are able to contribute a wide range of perspectives and scientific knowledge, we hope to foster the next breakthroughs in cancer vaccine research so that people diagnosed with cancer will have the opportunity to live longer and better lives.”
Cancer remains the second leading cause of death in the United States, claiming more than 600,000 lives each year, while millions more live with the fear of recurrence. Cancer vaccines represent a potential shift in how cancer is treated, and, ultimately, prevented.
Therapeutic cancer vaccines are designed to train the immune system to recognize and eliminate cancer cells, with the goal of durable, long-term immune protection. Clinical trials are currently underway across multiple cancer types, including glioblastoma, melanoma, pancreatic, breast, ovarian, and liver cancers, with early studies showing promising signals of immune response and clinical benefit.
One such example is Brad Silver, who received a therapeutic cancer vaccine for stage IV glioblastoma in 2003. At the time, he was given just two months to live. Twenty-two years later, Silver is thriving.
“I am not supposed to be here,” said Silver, who was treated in an early stage clinical trial of DCVax-L at UCLA. “The world views a stage IV glioblastoma diagnosis as a death sentence, but I’m living proof that a different outcome could be possible thanks to this clinical research. I wish everyone facing cancer could have access to vaccine-based treatments.”
The Global Think Tank is supported by HSBC Innovation Banking, Northwest Biotherapeutics, Pfizer and Anixa Biosciences.
About the Cancer Vaccine Coalition
The Cancer Vaccine Coalition (CVC) is a nonprofit organization dedicated to accelerating the development of therapeutic cancer vaccines to treat cancer and help prevent recurrence. Founded by former NBC
TODAY Show and
Nightly News correspondent Kristen Dahlgren, CVC is guided by survivors and scientists. It is the only nonprofit solely focused on advancing cancer vaccines by convening researchers and cross-sector partners to move the field into its next phase of coordinated clinical progress. CVC helps fund high-impact clinical trials and works to overcome barriers slowing progress, shortening the path from promising science to real-world patient impact. Learn more at
www.cancervaccinecoalition.org
About American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 61,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 143 countries and territories around the world. Presently, 34% of members live outside the United States and 20% of AACR’s international members are located in countries building cancer research capacity. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer through education, communication, collaboration, science policy and advocacy, and funding for cancer research. For more information about the AACR, visit
www.AACR.org.
About Northwest Biotherapeutics, Inc
Northwest Biotherapeutics (NWBio) is a biotechnology company focused on developing DCVax
® personalized dendritic cell-based cancer vaccines for solid tumor cancers. The Company has developed two versions of the DCVax platform technology: DCVax
®-L for operable tumors and DCVax
®-Direct for inoperable tumors. To date, NWBio has treated approximately 20 diverse types of solid tumor cancers and has completed a 331-patient international Phase 3 trial of DCVax-L for glioblastoma brain cancer, with an application for commercial approval in the U.K.
About HSBC Innovation Banking
HSBC Innovation Banking is the specialized banking partner for high-growth companies and their investors across the innovation economy. In the United States, services are provided by HSBC Bank USA, N.A., offering tailored financial solutions including commercial banking, venture debt, and treasury services. HSBC Innovation Banking combines deep sector expertise with the global capabilities of the HSBC Group to support innovative businesses as they scale domestically and internationally. Deposit products in the U.S. are offered by HSBC Bank USA, N.A., Member FDIC.
Name: Aliza Friedlander
Email:
[email protected]Phone: 443.858.0098
www.cancervaccinecoalition.org
SOURCE Cancer Vaccine Coalition
Leave a Reply